ArticleCancer cell2021
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 275 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
275citing papers in PubMed, 1 pooled it
27.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
275 citing papers in PubMed, 1 synthesis or guideline pooled it, 416 citations in OpenAlex.
- Single-cell meta-analysis of T cells reveals clonal dynamics of response to checkpoint immunotherapy.Cell genomics · 2025Pooled it
- 4-1BBCell reports. Medicine · 2025Trial
- Distinct CD8Cancer cell · 2025Trial
- Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial.Nature communications · 2025Trial
- A four‑gene signature identifies TKI‑induced persister cells and uncovers a ZLN005‑induced pyroptotic vulnerability via the GSDME pathway in EGFR‑mutant lung cancer.Molecular medicine reports · 2026Article
- Machine learning and multi-omics clustering to map cellular rewiring and immune evasion in ccRCC.Human genomics · 2026Article
- scXpand: Pan-cancer detection of T cell clonal expansion from single-cell RNA sequencing without paired single-cell TCR sequencing.Cell genomics · 2026Article
- Molecular heterogeneity and clonal origin of CCR8Nature communications · 2026Article
- Driving tumor-associated macrophages to a CXCL9Cell reports. Medicine · 2026Article
- APOEScience advances · 2026Article
- UPR-CEBPB-MIF Signaling Links to Macrophage Polarization and an Immunosuppressive Tumor Microenvironment in Clear Cell Renal Cell Carcinoma.Annals of surgical oncology · 2026Article
- Multi-omic characterization of 14q deletion in renal clear cell carcinoma identifiesJournal for immunotherapy of cancer · 2026Article
- Local, but not circulating, complement C3 shapes immune checkpoint blockade efficacy by controlling myeloid cell infiltration.Nature communications · 2026Article
- Article
- Transcriptomic analysis of tissue-resident memory T cells of the fallopian tube reveals a precursor immune surveillance network for ovarian cancer prevention.Nature communications · 2026Article
- Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma.Cancer cell · 2026Article
- Clonal lineage tracing of innate immune cells in human cancer.Cancer cell · 2026Article
- CXCL13-CXCR5 signaling in CD8Cancer immunology, immunotherapy : CII · 2026Article
- Pan-cancer atlas of cellular architecture reveals a nearest-neighbour distance-associated biomechanical-immune axis involving CD4+ memory T cells.Clinical and translational medicine · 2026Article
- FN1Oncogene · 2026Article
215 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
33 authors at 3 institutions in 1 country.
Chirag KrishnaComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Renzo G DiNataleImmunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Fengshen KuoImmunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Raghvendra M SrivastavaImmunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Lynda VuongImmunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Diego ChowellImmunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sounak GuptaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Chad VanderbiltDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Tanaya A PurohitImmunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ming LiuImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Emily KanslerImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Briana G NixonImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY 10065, USA.
Ying-Bei ChenDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Vladimir MakarovImmunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kyle A BlumImmunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kyrollis AttallaUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Stanley WengUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Michael L SalmansIllumina, Inc., 5200 Illumina Way, San Diego, CA 92122, USA.
Mahdi GolkaramIllumina, Inc., 5200 Illumina Way, San Diego, CA 92122, USA.
Li LiuIllumina, Inc., 5200 Illumina Way, San Diego, CA 92122, USA.
Shile ZhangIllumina, Inc., 5200 Illumina Way, San Diego, CA 92122, USA.
Raakhee VijayaraghavanIllumina, Inc., 5200 Illumina Way, San Diego, CA 92122, USA.
Traci PawlowskiIllumina, Inc., 5200 Illumina Way, San Diego, CA 92122, USA.
Victor ReuterDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Maria I CarloDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, NY 10065, USA.
Martin H VossDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, NY 10065, USA.
Jonathan ColemanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Paul RussoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Robert J MotzerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, NY 10065, USA.
Ming O LiImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Christina S LeslieComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: cleslie@cbio.mskcc.org.
Timothy A ChanImmunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH 44195, USA; Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA; National Center for Regenerative Medicine, Cleveland Clinic, Cleveland, OH 44195, USA. Electronic address: chant2@ccf.org.
A Ari HakimiImmunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: hakimia@mskcc.org.
Memorial Sloan Kettering Cancer Center · USIllumina (United States) · USCleveland Clinic · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTumor-specific T cell state dynamics and heterogeneity in early tumorigenesisU54CA209975 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LESLIE, CHRISTINA S, RUDENSKY, ALEXANDER Y · 2016 to 2021
$11.8MUROLOGY ONCOLOGY RESEARCH TRAINING GRANTT32CA082088 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Brett Stewart Carver · 1999 to 2026
$7.1MTOWARDS PRECISION IMMUNO-ONCOLOGY: UNRAVELING THE GENOMIC DETERMINANTS AND MECHANISMS UNDERLYING IMMUNOTHERAPY EFFICACY AND RESISTANCER35CA232097 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHAN, TIMOTHY AN-THY · 2018 to 2024
$7.0MElucidating genetics of response to immune checkpoint blockade in lung cancerR01CA205426 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CHAN, TIMOTHY AN-THY, RIZVI, NAIYER A · 2017 to 2021
$3.2MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA205426NCI NIH HHS R35 CA232097NCI NIH HHS T32 CA082088NCI NIH HHS U54 CA209975
Abstract
Clear cell renal cell carcinomas (ccRCCs) are highly immune infiltrated, but the effect of immune heterogeneity on clinical outcome in ccRCC has not been fully characterized. Here we perform paired single-cell RNA (scRNA) and T cell receptor (TCR) sequencing of 167,283 cells from multiple tumor regions, lymph node, normal kidney, and peripheral blood of two immune checkpoint blockade (ICB)-naïve and four ICB-treated patients to map the ccRCC immune landscape. We detect extensive heterogeneity within and between patients, with enrichment of CD8A
Indexed as
Carcinoma, Renal CellHumansKidney NeoplasmsLymphocyte ActivationProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellT-LymphocytesProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-Cellimmunotherapypathologyrenal cell carcinomasingle-cell RNA-sequencingTCR sequencingtissue-residenttumor-associated macrophagestyrosine kinase inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.